Healthcare / Medical DevicesNasdaqCM
$1.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-44.8M · quality 33.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$196M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-530.4%
↓Gross Margin
-41.7%
↓Debt/Equity
2.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-992.0%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.7M · net income $-58.0M · FCF $-46.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $4.7M | $4.7M | $4.3M | $2.4M | $377000.00 | $500000.00 | — |
| Net Income | $-58.0M | $-58.0M | $-45.5M | $-52.7M | $-56.2M | $-28.1M | $-8.3M |
| EBITDA | $-57.1M | $-57.1M | $-44.3M | $-49.8M | $-54.2M | $-27.4M | — |
| EPS | -0.43 | -0.43 | -1.05 | -1.26 | -1.55 | -1.51 | — |
| Gross Margin | -41.7% | -41.7% | -63.3% | -146.3% | -858.6% | 100.0% | — |
| Operating Margin | -1054.8% | -1054.8% | -1059.6% | -1996.8% | -14920.7% | -5483.8% | — |
| Net Margin | -1232.7% | -1232.7% | -1047.6% | -2169.1% | -14899.5% | -5615.6% | — |
| Balance Sheet | |||||||
| Debt/Equity | 2.36 | 2.36 | 3.94 | -6.60 | 0.09 | — | — |
| Current Ratio | 1.07 | 1.07 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-46.7M | $-46.7M | $-44.8M | $-33.0M | $-30.6M | $-18.5M | — |
| Returns | |||||||
| ROE | -530.4% | -530.4% | -844.5% | 2278.9% | -243.7% | -51.3% | 61.3% |
| Valuation | |||||||
| P/B | 15.46 | 15.46 | 7.68 | — | 2.01 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 8.3% | 8.3% | 79.0% | 544.0% | — | — | — |
| EPS Growth | 59.0% | 59.0% | 16.7% | 18.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.05 → -0.43
Residual
-25.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.